Specific protection against breast cancers by cyclin D1 ablation
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Breast cancer is the most common malignancy among women. Most of these cancers overexpress cyclin D1, a component of the core cell-cycle machinery. We previously generated mice lacking cyclin D1 using gene targeting. Here we report that these cyclin D1-deficient mice are resistant to breast cancers induced by the neu and ras oncogenes. However, animals lacking cyclin D1 remain fully sensitive to other oncogenic pathways of the mammary epithelium, such as those driven by c-myc or Wnt-1. Our analyses revealed that, in mammary epithelial cells, the Neu-Ras pathway is connected to the cell-cycle machinery by cyclin D1, explaining the absolute dependency on cyclin D1 for malignant transformation in this tissue. Our results suggest that an anti-cyclin D1 therapy might be highly specific in treating human breast cancers with activated Neu-Ras pathways.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“genetically engineered mouse models clearly revealed the importance of cyclin D1-CDK4 activity for the initiation and maintenance of HER2-driven breast cancers (98-100)”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [98]
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
β-Catenin regulates expression of cyclin D1 in colon carcinoma cells
Tetsu, O., & McCormick, F. (1999) · Nature · doi:10.1038/18884 · Cited by 3,601
Cyclin D1 Expression Is Regulated Positively by the p42/p44 and Negatively by the p38/HOG Pathway
Lavoie, J. N., L'Allemain, G., Brunet, A., Müller, R., & Pouysségur, J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.34.20608 · Cited by 1,211 · cited 1×
“Discussion The ras oncogene, acting through the mitogen-activated protein kinase pathway, is known to induce cyclin D1 by acting on cyclin D1 promote”
BackgroundMuller, W. J., Sinn, E., Pattengale, P. K., Wallace, R., & Leder, P. (1988) · Cell · doi:10.1016/0092-8674(88)90184-5 · Cited by 1,165
Cyclin D1 provides a link between development and oncogenesis in the retina and breast
Sicinski, P., Donaher, J. L., Parker, S. B., Li, T., Fazeli, A., Gardner, H., Haslam, S. Z., Bronson, R. T., Elledge, S. J., & Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90034-9 · Cited by 1,021
Bargmann, C. I., Hung, M.-C., & Weinberg, R. A. (1986) · Cell · doi:10.1016/0092-8674(86)90779-8 · Cited by 1,006
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice
Wang, T. C., Cardiff, R. D., Zukerberg, L., Lees, E., Arnold, A., & Schmidt, E. V. (1994) · Nature · doi:10.1038/369669a0 · Cited by 965
Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes
Stewart, T. A., Pattengale, P. K., & Leder, P. (1984) · Cell · doi:10.1016/0092-8674(84)90257-5 · Cited by 899
Transforming p21 Mutants and c-Ets-2 Activate the Cyclin D1 Promoter through Distinguishable Regions
Albanese, C., Johnson, J., Watanabe, G., Eklund, N., Vu, D., Arnold, A., & Pestell, R. G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.40.23589 · Cited by 803
Sinn, E., Muller, W., Pattengale, P., Tepler, I., Wallace, R., & Leder, P. (1987) · Cell · doi:10.1016/0092-8674(87)90449-1 · Cited by 792
Cited by
Items 601–700 of 937
Perez‐Gracia, J. L., Ruiz-Ilundáin, M. G., Garcia‐Ribas, I., & Carrasco, E. (2002) · Cancer · doi:10.1002/cncr.10877 · Cited by 30
“The proof of the existence of cancer-protective genetic alterations comes from the description of the resistance to develop breast carcinoma induced by the neu and ras oncogenes, as observed in mice lacking the cyclin D1 gene.(28) Although the cyclin D1 inactivation in these mice was induced artificially,(29,30) the r…”
BackgroundHsiang, C., & Straus, D. S. (2002) · Oncogene · doi:10.1038/sj.onc.1205293 · Cited by 29
“Moreover, cyclin D1 plays an essential role in malignant transformation of breast cancers induced by the neu and ras oncogenes (Yu et al., 2001).”
BackgroundYe, L. U. O., Hao, Y., Shi, T., Wei-wei, D. E. N. G., & Li, N. (2008) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2008.00786.x · Cited by 26
Caldon, C. E., Swarbrick, A., Lee, C. S. L., Sutherland, R. L., & Musgrove, E. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3079 · Cited by 28
“Furthermore, Ras can either increase or depend on Id1 expression in some model systems (44, 45), and cyclin D1 dependence is a feature of mammary oncogenesis induced by Ras (46, 47).”
BackgroundInfluentialProteotypic classification of spontaneous and transgenic mammary neoplasms
Mikaelian, I., Blades, N. J., Churchill, G. A., Fancher, K. S., Knowles, B. B., Eppig, J. T., & Sundberg, J. P. (2004) · Breast Cancer Research · doi:10.1186/bcr930 · Cited by 29
“However, Myc-and Wnt1-induced neoplasms are independent of cyclin D1, whereas Hrasand Neu-induced carcinomas are dependent on cyclin D1 [12,54], indicating that tumor phenotype and tumor genotype are not consistently matched.”
The Reciprocal Dance between Cancer and Development
Chodosh, L. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmcibr020712 · Cited by 29
Giugliano, F., Angelis, C. D., Pistilli, B., Viale, G., Bianchini, G., Giuliano, M., Malorni, L., Salimbeni, B. T., Espósito, A., Giordano, A., et al. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102980 · Cited by 26
Application of DODMA and Derivatives in Cationic Nanocarriers for Gene Delivery
Zhou, C., Zhang, A., Yang, Z., Wang, X., Chang, L., Chen, Z., & Lee, L. J. (2016) · Current Organic Chemistry · doi:10.2174/1385272820666160202004348 · Cited by 25
Shen, Q., Uray, I. P., Li, Y., Zhang, Y., Hill, J. L., Xu, X.-C., Young, M. R., Gunther, E. J., Hilsenbeck, S. G., Colburn, N. H., et al. (2008) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-08-0034 · Cited by 25
“(37) investigated the effect of ablation of cyclin D1 in MMTV-c-Myc, MMTV-Wnt1, MMTVras, andMMTV-erbB2 mice.”
BackgroundOloumi, A., Maidan, M. M., Lock, F. E., Tearle, H., McKinney, S. E., Muller, W. J., Aparicio, S. A. J. R., & Dedhar, S. (2010) · Breast Cancer Research · doi:10.1186/bcr2592 · Cited by 37
“Previous studies have shown an increased abundance of cyclin D1 in Wnt1 mammary tumors [34,35].”
ResultNovotný, J., Bandúrová, V., Strnad, H., Chovanec, M., Hradilová, M., Šáchová, J., Šteffl, M., Grušanović, J., Kodet, R., Pačes, V., et al. (2020) · Cancers · doi:10.3390/cancers12040792 · Cited by 26
“The importance of D-type cyclins for tumorigenesis has been demonstrated in mouse models, where the presence of cyclin D proteins is required for both tumor initiation and maintenance, while they seem largely dispensable for normal development [39,40].”
BackgroundCell facilitation promotes growth and survival under drug pressure in breast cancer
Emond, R., Griffiths, J. I., Grolmusz, V. K., Nath, A., Chen, J., Medina, E. F., Sousa, R. S., Synold, T. W., Adler, F. R., & Bild, A. H. (2023) · Nature Communications · doi:10.1038/s41467-023-39242-6 · Cited by 30
Post-transplantation malignancy: a cell autonomous mechanism with implications for therapy.
Suthanthiran, M., Hojo, M., Maluccio, M. A., Boffa, D. J., & Luan, F. L. (2009) · PubMed Central · Cited by 24
Cell Cycle-Based Therapies Move Forward
Malumbres, M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.024 · Cited by 25
Wang, K., Ma, Q., Ren, Y., He, J., Zhang, Y., Zhang, Y., & Chen, W. (2007) · Oncology Reports · doi:10.3892/or.17.1.89 · Cited by 27
Popescu, N. C., & Zimonjic, D. B. (2002) · American Journal of Medical Genetics · doi:10.1002/ajmg.10696 · Cited by 24
Amerizadeh, F., Rahmani, F., Maftooh, M., Nasiri, S. N., Hassanian, S. M., Giovannetti, E., Moradi‐Marjaneh, R., Sabbaghzadeh, R., Shahidsales, S., Joudi‐Mashhad, M., et al. (2022) · Tissue and Cell · doi:10.1016/j.tice.2022.101853 · Cited by 23
Alam, S., Zunic, A., Venkat, S., Feigin, M. E., & Atanassov, B. S. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0259 · Cited by 25
The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer
Gomes, I., Abreu, C., Costa, L., & Casimiro, S. (2023) · Cancers · doi:10.3390/cancers15194835 · Cited by 27
Zhang, F., Wang, Z., Yuan, J., Wei, X., Tian, R., & Niu, R. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3529-6 · Cited by 24
Downregulation and antiproliferative role of fhl3 in breast cancer
Niu, C., Yan, Z., Cheng, L., Zhu, J., Zhang, H., Xu, X., Lin, J., & Ye, Q. (2011) · IUBMB Life · doi:10.1002/iub.502 · Cited by 23
Kong, G., Chua, S. S., Yi, Y., Kittrell, F. S., Moraes, R., Medina, D., & Said, T. K. (2002) · Oncogene · doi:10.1038/sj.onc.1205895 · Cited by 24
“…luminal epithelial cells in mammary tumors, as cyclins D1 and D2 were detected in mouse mammary tumors after overexpression of wnt-1 and myc genes (Yu et al., 2001) Overexpression of cyclin D2 targeted to the mammary gland resulted in altered morphogenesis that was most evident during pregnancy.”
BackgroundKwak, Y.-T., Radaideh, S. M., Ding, L., Li, R., Frenkel, E. P., Story, M. D., Girard, L., Minna, J. D., & Verma, U. N. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0248 · Cited by 26
“Overexpression and altered subcellular distribution are implicated in the pathogenesis of a variety of tumors including breast, lung, colon, andmantle cell lymphoma (43, 44).”
BackgroundTargeting the Wnt Pathway in Cancer
Goss, K. H., & Kahn, M. R. (2011) · Springer eBooks · doi:10.1007/978-1-4419-8023-6 · Cited by 24
Wnt-Cadherin Connections in Normal and Neoplastic Mammary Epithelium
Méniel, V. S., & Clarke, A. R. (2003) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/b:jomg.0000017430.12210.37 · Cited by 23
“(56) have, however, dramatically shown that Wnt1-mediated tumorigenesis appears to be independent of cyclin D1 status, in stark contrast to both neu- and ras-mediated mammary neoplasia.”
BackgroundMayven induces c-Jun expression and cyclin D1 activation in breast cancer cells
Bu, X., Avraham, H. K., Li, X., Lim, B., Jiang, S., Fu, Y., Pestell, R. G., & Avraham, S. (2005) · Oncogene · doi:10.1038/sj.onc.1208466 · Cited by 23
“Cyclin D1 antisense treatment blocks mammary tumor growth in vivo (Lee et al., 2000) and cyclin D1 knockout Oncogene mice are resistant to mammary tumor development by ras (Fantl et al., 1995; Yu et al., 2001).”
BackgroundMouse Models of Cell Cycle Regulators: New Paradigms
Aleem, E. A., & Kaldis, P. (2006) · Springer eBooks · doi:10.1007/400_023 · Cited by 25
Wang, J., Wang, Z., Sun, Y., & Liu, D. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.03.014 · Cited by 22
Liu, J., Wang, X., Deng, Y., Yu, X., Wang, H., & Li, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.766248 · Cited by 27
“The pharmacologic inhibitors of CDK4/6 have been found to have a significant activity against several solid tumors (160, 161).”
BackgroundBishayee, A., & Mandal, A. (2014) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2014.01.002 · Cited by 23
To, S. Q., Knower, K. C., & Clyne, C. D. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.02.058 · Cited by 22
Novel arylazopyrazole inhibitors of cyclin-dependent kinases
Jorda, R., Schütznerová, E., Cankař, P., Brychtová, V., Navrátilová, J., & Kryštof, V. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.03.025 · Cited by 22
Identification of HLA ligands and T-cell epitopes for immunotherapy of lung cancer
Neumann, A., Hörzer, H., Hillen, N., Klingel, K., Schmid-Horch, B. D., Bühring, H., Rammensee, H., Aebert, H., & Stevanović, S. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1454-2 · Cited by 26
Skp2 knockout reduces cell proliferation and mouse body size: and prevents cancer?
Zhu, L. (2010) · Cell Research · doi:10.1038/cr.2010.71 · Cited by 22
Chiu, H., Lin, H.-Y., Tseng, I.-J., Hsiao, M., & Lin, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.23074 · Cited by 23
“In contrast, the NF-κB-related pathway was known to control cell growth by regulating the cell cycle machinery such as cyclins D1 [27, 28] which plays as a key element in mammary gland development and breast carcinogenesis [29].”
BackgroundCostantino, V. V., Lobos‐González, L., Ibáñez, J. E., Fernández, D., Cuello-Carrión, F. D., Valenzuela, M., Barbieri, M. A., Semino, S. N., Jahn, G. A., Quest, A. F. G., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.12.004 · Cited by 25
Frijhoff, A. F. W., Conti, C. J., & Senderowicz, A. M. (2004) · Molecular Carcinogenesis · doi:10.1002/mc.20013 · Cited by 24
Hojilla, C. V., Kim, I., Kassiri, Z., Fata, J. E., Fang, H., & Khokha, R. (2007) · Journal of Cell Science · doi:10.1242/jcs.003335 · Cited by 37
Preclinical and Clinical Studies
Brewster, M. E., Verreck, G., Bevernage, J., Brouwers, J., den Mooter, G. V., & Augustijns, P. (2015) · Wiley eBooks · doi:10.1002/9780470571224.pse529 · Cited by 22
Leptin regulates cyclin D1 in luminal epithelial cells of mouse MMTV-Wnt-1 mammary tumors
Zheng, Q., Hursting, S. D., & Reizes, O. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1252-9 · Cited by 21
Noninvasive PET Imaging of CDK4/6 Activation in Breast Cancer
Ramos, N. N., Baquero‐Buitrago, J., Youss, Z. B., Wadghiri, Y. Z., Reiner, T., Boada, F. E., & Carlucci, G. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.232603 · Cited by 21
“Amplification of CDK4/6 and cycD1 has been reported in a significant number of cancers and the overexpression of cycD1 was observed in >60% of all breast cancers (14,18-20).”
BackgroundLi, Y., Yi, H., Yao, Y., Liao, X., Xie, Y., Yang, J., Yan, Z., Wang, L., Lu, S., Kuang, Y., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019102 · Cited by 21
“The Cyclin D1 protein is a cell cycle regulator that functions to promote cellular proliferation and transformation through inhibiting the retinoblastoma pRB protein [49,50].”
BackgroundPromotion of breast cancer by β-Hexachlorocyclohexane in MCF10AT1 cells and MMTV-neu mice
Wong, P., & Matsumura, F. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-130 · Cited by 21
“[12].”
Hu, H., Hu, Y., Li, N., & Zhu, Y. H. (2009) · Oligonucleotides · doi:10.1089/oli.2008.0174 · Cited by 21
“Conversely, cyclin D1 – / – mice were resistant to mammary tumorigenesis induced by either ErbB2 or Ras (Yu et al., 2001), consistent with earlier studies using cyclin D1 antisense to decrease the expression of cyclin D1 (Lee et al., 2000).”
Misexpression of cyclin D1 in embryonic germ cells promotes testicular teratoma initiation
Lanza, D. G., Dawson, E. P., Rao, P., & Heaney, J. D. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1149272 · Cited by 23
“For example, in female mice bearing Erb2-driven mammary adenocarcinomas, Ccnd1 deficiency suppresses tumor cell proliferation and induces senescence, which together inhibit tumor initiation and growth.(50) Importantly, tumor cells appear to be uniquely dependent on the expression of individual D-type cyclins for their…”
BackgroundEryılmaz, O., Ateş, P. S., Ünal, İ., Üstündağ, Ü. V., Bay, S., Alturfan, A. A., Yiğitbaşı, T., Emekli‐Alturfan, E., & Akalın, M. (2017) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22015 · Cited by 24
Huang, X., Wang, Y., Hong, P., Yang, J., Zheng, C., Yin, X., Song, W., Xu, W. W., Li, B., & He, Q. (2019) · PubMed Central · Cited by 21
Zhu, L., Shen, X., Yuan, P., Shao, T., Wang, G.-D., & Liu, X. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117983 · Cited by 23
Effects of an Indolocarbazole-Derived CDK4 Inhibitor on Breast Cancer Cells
Sun, Y., Li, Y., Wu, H., Wu, S.-H., Wang, Y., Luo, D., & Liao, D. J. (2011) · Journal of Cancer · doi:10.7150/jca.2.36 · Cited by 27
“Besides these alterations shared by other malignancies, D1 is exceptionally important for the mammary gland and breast cancer for two specific reasons: 1) it is the only D type cyclin expressed in the mammary gland and controls mammary gland development [7]; 2) it is a major downstream effector of estrogen receptors […”
BackgroundDevelopment of New Prolactin Analogs Acting as Pure Prolactin Receptor Antagonists
Goffin, V., Bernichtein, S., Kayser, C., & Kelly, P. A. (2003) · Pituitary · doi:10.1023/b:pitu.0000004799.41035.9f · Cited by 21
“Also, recent observations demonstrated that PRL activates the expression of various proteins known to be key players in breast cancer progression, such as cyclin D1 [12,13], or IGF-2, recently identified as a putative relay of some PRL actions in the breast [14,15].”
BackgroundProtein kinases in mammary gland development and cancer
Kumar, R., & Wang, R. (2002) · Microscopy Research and Technique · doi:10.1002/jemt.10176 · Cited by 22
“Consequently, knocking out of cyclin D1 was found to confer the mice resistance to stimulation of HER2 and Ras, but not c-myc and Wnt-1 (Yu et al., 2001).”
BackgroundPre-Clinical Applications of Transgenic Mouse Mammary Cancer Models
Kavanaugh, C. J., Desai, K. V., Calvo, A., Brown, P. H., Couldrey, C., Lubet, R. A., & Green, J. E. (2002) · Transgenic Research · doi:10.1023/a:1021159705363 · Cited by 21
“The investigators found that neu and ras tumors preferentially express cyclin D1, while the c-myc and WNT models express cyclin D1 and cyclin D2 (Yu et al., 2001).”
BackgroundInfluentialGarrido-Castro, A. C., Graham, N., Ali, L. R., Herold, C. I., Desrosiers, J., Do, K., Parsons, H. A., Li, T., Goel, S., DiLullo, M. K., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010430 · Cited by 21
Rajakumar, T., & Pugalendhi, P. (2023) · Histochemistry and Cell Biology · doi:10.1007/s00418-023-02255-9 · Cited by 23
“Cyclin D1 is a cell cycle regulatory nuclear protein that controls cell proliferation and differentiation by contributing cellular mechanisms from G1 to S phase (Yu et al. 2001).”
Sarkar, S., Rajput, S., Tripathi, A. K., & Mandal, M. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-122 · Cited by 23
“The alteration of both cyclin D1 and cyclin E was associated with breast cancer progression, early relapse, poor prognosis and chemo-resistance to various cytotoxic agents [57-59].”
Lee, S. J., Lee, J. S., Lee, E., Lim, T., & Byun, S. (2018) · Journal of Functional Foods · doi:10.1016/j.jff.2018.04.050 · Cited by 21
Sequence dependent potentiation of gemcitabine by flavopiridol in human breast cancer cells
Ali, S. S., El-Rayes, B. F., Aranha, O., Sarkar, F. H., & Philip, P. A. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-2179-x · Cited by 20
“For example, approximately 50% of ductal adenocarcinomas over express cyclin D1 [2].”
BackgroundHuang, S., Chen, Y., Podsypanina, K., & Li, Y. (2008) · Neoplasia · doi:10.1593/neo.07637 · Cited by 21
“[32] Yu Q, Geng Y, and Sicinski P (2001).”
BackgroundBernards, R. (2004) · Nature Genetics · doi:10.1038/ng0404-319 · Cited by 20
The Effects of HER2 on CDK4/6 Activity in Breast Cancer
Sinclair, W., & Cui, X. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.08.007 · Cited by 21
MicroRNA-218 inhibits the proliferation of human choriocarcinoma JEG-3 cell line by targeting Fbxw8
Shi, D., Tan, Z., Lu, R., Yang, W., & Zhang, Y. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.06.094 · Cited by 19
“As a result, it is a potential target for cancer therapeutics [34].”
Forti, F. L., & Armelin, H. A. (2007) · Endocrine Related Cancer · doi:10.1677/erc-07-0154 · Cited by 19
“Cyclin D1K/K knockout mice, but not D2K/K and D3K/K knockout mice, are viable and protected from mammary cancer driven by MMTV-ras or MMTV-neu oncogenes (Yu et al. 2001).”
BackgroundInfluentialA novel targeted therapy in breast cancer: cyclin dependent kinase inhibitors.
Akın, S., Babacan, T., Sarici, F., & Altundağ, K. (2014) · PubMed · Cited by 24
Abemaciclib, a CDK4 and CDK6 Inhibitor for the Treatment of Metastatic Breast Cancer
Martín, M., García-Sáenz, J. Á., Manso, L., Llombart‐Cussac, A., Cassinello, A., Atienza, M., Ringeisen, F. P., & Ciruelos, E. (2020) · Future Oncology · doi:10.2217/fon-2020-0604 · Cited by 20
Akkol, E. K., Bardakçı, H., Barak, T. H., Aschner, M., Karatoprak, G. Ş., Khan, H. Z., & Hussain, Y. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/6044640 · Cited by 27
“Although cyclin D1 knockout mice were shown to be resistant to the formation of Erbb2 or Ras oncogene-induced breast cancers, cyclin D1 de fi ciency has not been shown to be protective against tumor formation induced by c-Myc or Wnt-1 [54].”
Chen, C., Chen, S.-Y., & Chen, C.-H. (2012) · Process Biochemistry · doi:10.1016/j.procbio.2012.05.018 · Cited by 19
The Tissue Microenvironment as an Epigenetic Tumor Modifier
Unger, M. A., & Weaver, V. M. (2003) · Humana Press eBooks · doi:10.1385/1-59259-329-1:315 · Cited by 20
Kinase independent oncogenic cyclin D1
Casimiro, M. C., Arnold, A., & Pestell, R. G. (2015) · Aging · doi:10.18632/aging.100773 · Cited by 19
Restoring order at the cell cycle border: Co-targeting CDK4/6 and CDK2
Jeselsohn, R. M., Schiff, R., & Grinshpun, A. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.08.007 · Cited by 18
Elango, R., Rashid, S., Vishnubalaji, R., Al-Sarraf, R., Akhtar, M., Ouararhni, K., Decock, J. V., Albagha, O., & Alajez, N. M. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05908-8 · Cited by 19
Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer
Pegram, M. D., Pietras, R. J., Dang, C. T., Murthy, R. K., Bachelot, T., Janni, W., Sharma, P., Hamilton, E. P., & Saura, C. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231187201 · Cited by 21
Kaplan, D. R., Meyerson, H. J., Husel, W., Lewandowska, K., & MacLennan, G. (2004) · Cytometry Part A · doi:10.1002/cyto.a.20103 · Cited by 19
“protected against the formation of breast cancers (15).”
BackgroundCDK4 deficiency promotes genomic instability and enhances Myc-driven lymphomagenesis
Lu, Y., Yong-sheng, W., Feng, X., Shen, R. Z., Wang, J. H., Fallahi, M., Li, W., Yang, C., Hankey, W., Zhao, W., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci63139 · Cited by 26
“In addition, loss or knockdown of CDK4 or cyclin-D1 disables RAS-and Neu-induced tumorigenesis (14, 21, 22), and a mutant form of cyclin D1 that binds to, but cannot activate, CDK4 also impairs Neu-induced tumorigenesis (23).”
Wang, X., Wang, C., Yan, G., Kang, Y., Sun, G., Wang, S., Zou, R., Sun, H., Zeng, K., Song, H., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102685 · Cited by 19
Iizuka, S., Oridate, N., Nashimoto, M., Fukuda, S., & Tamura, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114121 · Cited by 22
“Ras), as mice deficient in cyclin D1 are resistant to tumorigenesis [33, 34].”
BackgroundMori, K., Hirao, E., Toya, Y., Oshima, Y., Ishikawa, F., Nose, K., & Shibanuma, M. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-04-0428 · Cited by 20
“Although in vivo experimental models for mammary tumor propose cyclin D1 as a downstream effector of oncogenic ras signaling and a necessary target of the ras and ErbB-2 oncogenes (Yu et al., 2001), the details remain unknown.”
BackgroundReddy, H. K. D. L., Graña, X., Dhanasekaran, D. N., Litvin, J., & Reddy, E. P. (2010) · Genes & Cancer · doi:10.1177/1947601909358105 · Cited by 27
Yang (2010) · International Journal of Oncology · doi:10.3892/ijo_00000608 · Cited by 20
“The D-type cyclins link the extracellular signals to the cell-cycle machinery and of the three D-type cyclins, it is cyclin D1 that is predominantly associated with human tumorigenesis (8).”
To NFκB or not to NFκB: The Dilemma on How to Inhibit a Cancer Cell Fate Regulator.
Sorriento, D., Illario, M., Finelli, R., & Iaccarino, G. (2012) · PubMed Central · Cited by 44
Proteomic analysis of the molecular response of Raji cells to maslinic acid treatment
Yap, W. H., Khoo, K. S., Lim, S. H., Yeo, C. C., & Lim, Y. M. (2011) · Phytomedicine · doi:10.1016/j.phymed.2011.08.058 · Cited by 17
In vivo Analysis of the Cyclin D1 Promoter during Early Embryogenesis in Xenopus
Tanaka, T., Kubota, M., Shinohara, K., Yasuda, K., & Kato, J. (2003) · Cell Structure and Function · doi:10.1247/csf.28.165 · Cited by 18
“recent report indicates that cyclin D1 specifically functions downstream of the Neu/Ras-mediated oncogenic signaling pathway during breast tumor development, and that nullification of the cyclin D1 gene protects mice from Neu/Rasinduced tumorigenesis (Robles et al., 1998; Yu et al., 2001).”
BackgroundCyclin d1 overexpression sensitizes breast cancer cells to fenretinide.
Pirkmaier, A., Yuen, K., Hendley, J., O’Connell, M. J., & Germain, D. (2003) · PubMed · Cited by 18
Comment développer et améliorer les actions de prévention dans le système de santé français ?
Tubiana, M., & Legrain, M. (2002) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)34349-3 · Cited by 24
Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2
Shagisultanova, E. I., Crump, L. S., Borakove, M., Hall, J., Rasti, A. R., Harrison, B. A., Kabos, P., Lyons, T. R., & Borges, V. F. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0098 · Cited by 17
“Indeed, cyclin D1 expression is a prerequisite for development of the tumors driven by HER2, as cyclin D1-deficient mice do not develop mammary tumors in HER2-driven models (20).”
BackgroundInhibiting CDK4/6 in pancreatic ductal adenocarcinoma via microRNA-21
Mortoglou, M., Miralles, F., Mould, R. R., Sengupta, D., & Onganer, P. U. (2023) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2023.151318 · Cited by 18
Kalderon, D. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-470-4_8 · Cited by 17
Cai, W., Sun, Y. K., Wang, W., Han, C., Ouchida, M., Xia, W., Zhao, X., & Sun, B. (2011) · Pathology & Oncology Research · doi:10.1007/s12253-010-9334-y · Cited by 22
“It was well established that a high expression of cyclin D1 is important for tumor cell proliferation and oncogenesis [16].”
BackgroundKunnath, A. P. (2014) · Journal of Cancer Science & Therapy · doi:10.4172/1948-5956.1000256 · Cited by 16
“The primary mechanism by which ErbB2 induces mammary tumorigenesis in human breast cancer is through activation of PI3K/ Akt and MAP kinase pathways ultimately affecting transcription factors and the machinery that controls the cell cycle, such as cyclin D1[14] as well as Cdk4, a known cyclin D1 partner [15,16].”
BackgroundSynthesis, anticancer, molecular docking and QSAR studies of benzoylhydrazone
Taha, M., Sultan, S., Herizal, M., Fatmi, M. Q., Selvaraj, M., Ramasamy, K., Halim, S. A., Lim, S. M., Rahim, F., Ashraf, K., et al. (2019) · Journal of Saudi Chemical Society · doi:10.1016/j.jscs.2019.07.007 · Cited by 16
Yasmeen, A., Hosein, A. N., Yu, Q., & Moustafa, A. A. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00504.x · Cited by 16
Self-citationZhang, C., Zhang, P., Hao, J., Quddus, M. R., Steinhoff, M. M., & Sung, C. J. (2005) · The Breast Journal · doi:10.1111/j.1075-122x.2005.21533.x · Cited by 16
“The role of cyclin D1 in breast cancer is further supported by a report showing resistance against breast cancer induction by the neu and ras oncogenes in cyclin D1-ablated mice (18).”
Backgroundvan Rossum, A. G. S. H., van Bragt, M. P. A., Schuuring-Scholtes, E., van der Ploeg, J. C., van Krieken, J. H., Kluin, P. M., & Schuuring, E. M. D. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-58 · Cited by 16
“Cyclin D1 appears to be critical in some pathways of mammary tumorigenesis, because cyclin D1-deficient mice are resistant to breast cancers induced by the c-neu and Ha-ras oncogene, but remain fully sensitive to breast cancers induced by c-myc and Wnt-1 [18].”
BackgroundQiu, C., Shan, L., Yu, M., & Snyderwine, E. G. (2003) · PubMed · Cited by 17
Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer
Liang, Y., Zhang, P., Li, F., Lai, H., Qi, T., & Wang, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1332539 · Cited by 22
Zheng, J., Liu, L., Wang, S., & Huang, X. (2015) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000501 · Cited by 15
“proliferation, division, and apoptosis are dependent on a normal cell cycle.(23) The cell cycle consists of 4 phases, G1 (DNA pre-synthesis), S (DNA synthesis), G2 (DNA postsynthesis), and M (mitosis).”
BackgroundPeek, G. W., & Tollefsbol, T. O. (2016) · Experimental Cell Research · doi:10.1016/j.yexcr.2016.03.022 · Cited by 16
“Additional cdk-dependent and cdk-independent effects of Cyclin D1 include suppression of p21 transcription and the accommodation of HER2/Neu and Ras-driven oncogenesis [70-71].”
BackgroundRibociclib plus fulvestrant in the treatment of breast cancer
Neven, P., Sonke, G. S., & Jérusalem, G. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1840360 · Cited by 16
Rac3-Mediated Transformation Requires Multiple Effector Pathways
Keller, P. J., Gable, C. M., Wing, M. R., & Cox, A. D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3116 · Cited by 15
“Rac1 is one of the most heavily studied members of the Rho subfamily of Ras-related small GTPases (1).”
BackgroundInfluentialTargeting cell cycle kinases and kinesins in anticancer drug development
Yap, T. A., Molife, L. R., Blagden, S. P., & Bono, J. S. D. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.4.539 · Cited by 14
“Since this initial finding that Cdk4 gene amplification and overexpression in sporadic breast carcinomas is associated with increased tumour cell proliferation [26], it has been demonstrated that mice lacking cyclin D1 are resistant to breast cancer triggered by the ErbB2 (HER-2) oncogene [30].”
BackgroundCDK4/6 Inhibitors resTORe Therapeutic Sensitivity in HER2 + Breast Cancer
Malumbres, M. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.016 · Cited by 14
“Pioneer work by Sicinski and collaborators demonstrated that cyclin D1 is essential for murine HER2-positive breast cancer (Yu et al., 2001), and further research led to similar conclusions for CDK4 requirements in these tumors (Landis et al., 2006; Yu et al., 2006).”
Background
Metadata
- Authors
- Yu, Q., Geng, Y., & Sicinski, P.
- Affiliations
- Harvard University (US)
- ORCID
- Yu, Qunyan
- Venue
- Nature
- Published
- 2001-06
- Volume
- 411
- Issue
- 6841
- Pages
- 1017-1021
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2098953839
- Cited by
- 934
- References
- 31
- Citations by year
- 2026: 9 · 2025: 5 · 2024: 12 · 2023: 26 · 2022: 19 · 2021: 24 · 2020: 32 · 2019: 22 · 2018: 24 · 2017: 36 · 2016: 25 · 2015: 33 · 2014: 32 · 2013: 33 · 2012: 35
- FWCI
- 33.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- cyclin D1, breast cancer, neu oncogene, oncogenic Ras, cell cycle, mammary epithelium, malignant transformation, c-Myc, Wnt1, targeted cancer therapy
- MeSH terms
- Animals, Antineoplastic Agents, Breast, Breast Neoplasms, Cell Transformation, Neoplastic, Crosses, Genetic, Female, Humans, Male, Mammary Tumor Virus, Mouse, Mammary Neoplasms, Experimental, Proto-Oncogene Proteins, Genes, ras, Tumor Cells, Cultured, Genes, myc, Genes, erbB-2, Cyclin D1, Genes, bcl-1, Genetic Predisposition to Disease, Zebrafish Proteins, Animals, Genetically Modified, Wnt Proteins, Wnt1 Protein, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.